Rational Development of Stable PYY3–36 Peptide Y2 Receptor Agonists-Reference-Cited by-同舟云学术

Rational Development of Stable PYY3–36 Peptide Y2 Receptor Agonists

Published:2021-07-16 Issue:8 Volume:38 Page:1369-1385
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Poulsen Christian^ORCID,Pedersen Marie Østergaard,Wahlund Per-Olof,Sjölander Annika,Thomsen Jens Kaalby,Conde-Frieboes Kilian W.,Paulsson Johan F,Wulff Birgitte S,Østergaard Søren

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s11095-021-03077-x.pdf

Reference53 articles.

1. Manning S, Batterham RL. The role of gut hormone peptide YY in energy and glucose homeostasis: twelve years on. Annu Rev Physiol. 2014;76(1):585–608.

2. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009;124(1):44–56.

3. Karra E, Batterham RL. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol. 2010;316(2):120–8.

4. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. Gut hormone PYY3-36 physiologically inhibits food intake. Nature. 2002;418(6898):650–4.

5. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM. Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia. 2013;56(6):1413–6.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

2. Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects;Pharmacology Research & Perspectives;2024-07-17

3. G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases;Acta Materia Medica;2024

4. Cross talk about the role of Neuropeptide Y in CNS disorders and diseases;Neuropeptides;2023-12

5. Evolution of peptide YY analogs for the management of type 2 diabetes and obesity;Bioorganic Chemistry;2023-11